SEATTLE, Sept. 11, 2019 /PRNewswire/ -- Immunexpress,
Inc. today announced that Jane Papadaki
Markley has joined the company's Executive Team as Vice
President of Market Development and Commercial Operations.
"Jane's impressive ability to incorporate the commercial
perspective into development strategies will be influential in our
upcoming launch planning for SeptiCyte™ RAPID," said Rolland D. Carlson, Ph.D., Chief Executive
Officer of Immunexpress. "Having worked with Jane twice before, I
am confident that her strength in leadership, operational
excellence and global launch experience will enable Immunexpress to
deliver on our performance goals. In line with our corporate
culture, Jane is deeply committed to creating innovative solutions
to complex medical problems, and I look forward to working
side-by-side as we implement her commercial initiatives."
Ms. Papadaki Markley added, "Immunexpress is a leader in the
sepsis diagnostic space and its first-in-class,
clinically-validated SeptiCyte™ technology platform can
significantly impact patients suspected of sepsis via a host
response signature. I look forward to utilizing my experience in
shifting diagnostic paradigms in the clinical marketplace and
introduce SeptiCyte™ to practitioners in healthcare systems
worldwide. I am pleased to join the team at Immunexpress as we work
to accelerate the accurate diagnosis of sepsis for critically ill
patient management decisions."
Ms. Papadaki Markley joins Immunexpress with over 30 years of
experience in the diagnostic and biotechnology marketplace where
she has been responsible for the global commercial launch of
products. Ms. Papadaki Markley's experience spans infectious
disease, immunology, oncology and genetic diseases. She served in
leadership positions at Takara Bio (via acquisition of Wafergen
Biosystems), ApoCell, Asuragen, Qiagen, Agendia and Quest
Diagnostics. Her experience as a commercial leader has resulted in
a track record of successfully drafting and executing strategic
sales and marketing initiatives, launching new products and
services, and enhancing the efficiency and profitability of
cross-functional teams. Ms. Papadaki Markley received her Bachelor
of Science in Zoology summa cum laude from the Imperial
College of Science & Technology at London University.
About Immunexpress
Immunexpress is a Seattle-based molecular diagnostic company
committed to improving outcomes for patients suspected of sepsis.
Immunexpress' SeptiCyte™ technology rapidly quantifies, directly
from whole blood, specific molecular markers from the patient's own
immune system – the 'host response'. SeptiCyte™ LAB, recently
cleared by the FDA, is the first of its kind in using the host
immune system to differentiate systemic inflammatory response
syndrome (SIRS) and sepsis. Detecting the host's response to
infection has the potential to differentiate infection earlier,
faster and more accurately than finding the invading pathogen
because it is independent of whether or not the pathogen is present
in the sample. Immunexpress' pipeline includes several
sample-to-answer assays for near-patient testing.
For more information visit http://www.immunexpress.com/.
Follow Immunexpress on Twitter and LinkedIn.
Media Contacts:
Maggie
Beller
Russo Partners, LLC
+1(646) 942-5631
Maggie.beller@russopartnersllc.com
View original
content:http://www.prnewswire.com/news-releases/immunexpress-appoints-jane-papadaki-markley-as-vp-of-market-development-and-commercial-operations-300915817.html
SOURCE Immunexpress, Inc.